Highlights

  • Amplia Therapeutics (ASX: ATX) has begun a pivotal registration-enabling trial of its lead pancreatic cancer drug candidate, narmafotinib, targeting a multi-billion-dollar global treatment market.
  • Advance Metals (ASX: AVM) is moving towards full ownership of its high-grade Victorian gold projects after fresh drilling and metallurgical work pointed to a bonanza-grade opportunity.
  • ClearVue Technologies (ASX: CPV) has secured global certification for its thermal management junction box, a core component in its building-integrated solar panels.
  • West Wits Mining (ASX: WWI) has locked in an A$74.4 million senior commercial Debt Facility with Absa and Nedbank CIB to fund its Qala Shallows gold project in South Africa.
  • Neometals (ASX: NMT) has uncovered multiple drill-ready copper targets at its Rinaldi prospect in Western Australia, hinting at a wider buried copper-silver system.

Australian small-cap stocks are once again drawing attention from retail traders, family offices and growth-focused fund managers as investors search for high-conviction stories beyond the ASX 200's banks, miners and supermarkets. Behind that interest sits a familiar pattern: company-specific catalysts — a clinical trial milestone, a funding deal, a permit, a high-grade drill hit, a global certification — capable of materially shifting a stock's outlook over a short time frame.

A snapshot of ASX micro-caps and small-caps making moves across biotech, gold, copper and clean-tech tells a similar story. Over the past week, fresh company updates have emerged from names including Amplia Therapeutics, Advance Metals, ClearVue Technologies, West Wits Mining and Neometals. Together, these companies show how Australian growth investors are increasingly looking at sectors where global market tailwinds, government policy support and rising Commodity prices can amplify company-specific progress.

Importantly, none of these companies are household names. Many sit well outside the ASX 300. That is precisely why they are attracting watchlist attention: the upside is tied to milestones that can rerate a stock if delivered, and the downside is being weighed against typical small-cap risks such as funding, dilution, execution and approval timelines.

Amplia Therapeutics (ASX: ATX): Pancreatic cancer drug enters pivotal trial

Among ASX biotech stocks, Amplia Therapeutics is one of the most closely watched small-caps this week. The clinical-stage drug developer has formally launched a pivotal, registration-enabling trial of its lead candidate, narmafotinib, in patients with advanced pancreatic cancer. The trial is also designed to evaluate a daily dosing regimen aimed at improving efficacy, and is positioned to potentially evolve into a full Phase 3 study under the United States Food and Drug Administration's regulatory framework.

Pancreatic cancer remains one of the most aggressive and difficult-to-treat solid tumours, with five-year survival rates still in the single digits in many countries. Industry estimates frequently size the global pancreatic cancer therapeutics market in the multi-billion-dollar range, with significant unmet medical need. That combination of clinical urgency and commercial scale is part of what is driving investor interest in Amplia's program.

For ASX small-cap biotech investors, pivotal trial readouts are typically the single largest valuation lever a developer can pull. Positive data could potentially open the door to Partnership conversations with global pharmaceutical companies, while negative data carries the well-known risk of a sharp drawdown. As a result, market attention may focus on enrolment milestones, interim safety readouts and any commentary from Amplia about the path towards a potential FDA-approved Phase 3 study.

Advance Metals (ASX: AVM): High-grade Victorian gold play in the spotlight

With gold trading near multi-decade highs in Australian dollar terms, ASX gold stocks have moved firmly back into focus, and small-cap explorers are once again competing for investor Capital. Advance Metals is one of the names pulling attention this week, after announcing plans to consolidate full ownership of its high-grade Victorian gold projects following encouraging drilling results and metallurgical testwork that pointed to what the company describes as a bonanza-grade opportunity.

Victoria's central goldfields have long held a reputation as some of the richest gold districts in the world, dating back to the 19th-century rushes. Modern exploration techniques have continued to deliver new high-grade discoveries, and several mid-tier ASX-listed gold producers have built their growth pipelines around the region. For investors, that historical context tends to amplify interest whenever a junior explorer like Advance Metals delivers strong assays.

The strategic angle behind the move to 100% ownership is straightforward: by reducing joint-venture or earn-in complexity, Advance Metals positions itself to capture the full upside of any future resource definition, scoping study or development decision. The trade-off, of course, is that the company also takes on the full exploration risk and capital cost. Investors watching ASX gold stocks may track follow-up drilling, resource updates and any indications of how the project could fit into Victoria's broader gold-producing landscape.

ClearVue Technologies (ASX: CPV): Solar tech certification opens global doors

Clean-tech remains a structural growth theme on the ASX, and ClearVue Technologies has emerged as one of the more visible small-cap stories thanks to its building-integrated photovoltaic (BIPV) glazing. Most recently, the company secured global certification for its thermal management junction box, a critical component within its solar window panels. The certification clears a meaningful international regulatory hurdle and is intended to support the broader global rollout of the company's solar glass products.

ClearVue's pitch sits at the intersection of two powerful long-term trends: the global push to decarbonise the built environment, and the rising importance of energy efficiency in Commercial Real Estate. By integrating solar generation directly into windows and facades, BIPV technologies aim to turn passive building surfaces into active power generators. As governments tighten building emissions standards in Europe, North America and parts of Asia, Demand for such solutions could continue to grow.

The momentum at ClearVue has been more than a single certification. The same week also saw the company announce a fresh contract worth around A$305,000 to Supply solar glazing for a commercial retrofit project in Cyprus, alongside a research grant and component certification news. Taken together, these updates have placed ClearVue back on watchlists of investors hunting ASX clean-tech and solar technology stocks with international commercial traction.

West Wits Mining (ASX: WWI): A$74.4M facility fuels South African gold push

Funding is often the make-or-break Factor for small-cap mining companies aiming to move from exploration into production. West Wits Mining has taken a major step in that direction by securing a senior commercial debt facility of A$74.4 million from South African banking heavyweights Absa and Nedbank CIB. The facility is earmarked to fund the development of the company's flagship Qala Shallows gold project.

From an investor perspective, the financing achievement is significant for several reasons. First, tier-one bank involvement implies a comprehensive Due Diligence process that typically scrutinises mine plans, cost assumptions and project Economics. Second, Debt Financing of this scale can reduce the need for additional Equity raisings, which often weigh on small-cap share prices. Third, it accelerates the path from a development-stage explorer towards a producing gold company, exposed to current high gold prices.

South Africa carries its own basket of risks for ASX-listed miners, including power supply reliability, mining regulation and currency Volatility. Investors watching ASX gold stocks with offshore exposure may consider how West Wits' funding package, project timelines and operating cost guidance compare with peers, and how the company plans to manage country-specific risks while gold prices remain elevated.

Neometals (ASX: NMT): Copper firepower added to WA gold hunt

Neometals has long been associated with battery materials and recycling technologies, but its latest update shifts attention to a more traditional exploration story. The company has identified multiple drill-ready copper targets at its Rinaldi prospect in Western Australia's Mid West, with induced polarisation (IP) survey results suggesting a potentially larger buried copper-silver system beneath and beyond historic workings.

The development matters because copper is increasingly viewed as one of the structural commodities of the energy transition. Demand drivers including electrification, electric vehicles, renewable power infrastructure and AI-driven data centre buildouts have helped underpin a strong medium-term outlook for copper prices. ASX-listed companies with credible exposure to new copper discoveries have therefore tended to draw both retail and institutional interest.

For Neometals, the copper targets add a new dimension to a portfolio better known for lithium recycling and titanium-vanadium projects. Investors may watch upcoming drilling timelines, target prioritisation and any read-through to nearby mineralisation. As with all early-stage exploration plays, the path from geophysical anomalies to a defined resource carries inherent risk.

Other small-cap movers worth knowing about

Beyond the five headline names, several other ASX small-caps have generated fresh news flow over the past week and may be worth adding to the broader watchlist.

Viking Mines (ASX: VKA)

Viking Mines has received federal United States approval for a 63-hole drilling campaign at its Linka tungsten project in Nevada. The program is designed to test high-grade targets in a market widely seen as short of domestic American tungsten supply. The company has also flagged the discovery of additional surface rock stockpiles showing widespread mineralisation under ultraviolet light, which may inform follow-up work.

Locksley Resources (ASX: LKY)

Locksley Resources has reported high-grade antimony mineralisation from diamond drilling beneath historic workings at its Desert Antimony Mine in California, with a standout assay of around 33.51% antimony. With antimony listed by several governments as a critical mineral for both defence and energy applications, results of this grade may attract continuing strategic interest.

Critical Resources (ASX: CRR)

Critical Resources has secured a worldwide exclusive licence for an NTU-developed cooling technology, broadening its activities into thermal management for batteries, GPUs and CPUs. The pivot taps into the growing importance of efficient heat management within data centres, electric vehicles and high-performance computing infrastructure.

Why these themes matter for ASX investors

Looking across these companies, three macro themes are reinforcing the small-cap narrative. Biotech, led by Amplia, is benefiting from renewed global interest in oncology Drug Development and a strong policy push towards faster regulatory pathways for serious, hard-to-treat diseases. Gold, represented by Advance Metals and West Wits, is being supported by record-high bullion prices, ongoing geopolitical uncertainty and Central Bank buying. Clean Technology, embodied by ClearVue and elements of Neometals and Critical Resources, is leveraging the global energy transition, the electrification of buildings and rising demand for critical minerals.

For Australian investors, the takeaway is not that any single ASX small-cap stock represents a guaranteed winner. The takeaway is that the catalyst calendar is alive again. With the ASX 200 mainly led by large-cap banks, miners and consumer staples, small-caps are where idiosyncratic upside often lives, and where company-specific news flow can move the share price within hours.

Key risks to keep in mind

Small-cap investing on the ASX comes with well-documented risks. Liquidity can be thin, share prices can swing sharply on a single announcement, capital raisings can dilute existing holders, and many development-stage companies are years away from generating sustainable Cash Flow. Biotech investors face the binary risk of clinical trial outcomes, exploration investors face the risk of disappointing assays or permitting setbacks, and clean-tech investors must judge whether early commercial traction can scale into a profitable Business.

Australian investors may consider their own time horizon, Risk tolerance and portfolio Diversification before adding individual small-cap names, and should be wary of relying on a single news cycle to drive decisions. Position sizing, in particular, often differentiates investors who can hold through volatility from those who become forced sellers at the worst moments.

What ASX investors may watch from here

Catalysts to monitor across these names include further enrolment and safety updates from Amplia Therapeutics' pivotal narmafotinib trial, additional drilling results and metallurgical work from Advance Metals in Victoria, new international solar rollouts and Revenue updates from ClearVue Technologies, project execution and gold pour milestones from West Wits Mining, and maiden drilling at Neometals' Rinaldi copper targets. Updates on Viking's Nevada tungsten drilling, follow-up at Locksley's California antimony mine and commercialisation progress at Critical Resources will also help refine the broader small-cap picture.

This article has been prepared by Kalkine for general informational purposes only, drawing on publicly available ASX announcements and company disclosures referenced throughout.